CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Atrial Fibrillation
Interventions
DEVICE

Arctic Front Advance® balloon catheter

Cryoablation of bidirectional block of all pulmonary veins

DRUG

Antiarrhythmic drug

The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.

DEVICE

Confirm RX heart monitor® (Abbott)

Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function

Trial Locations (1)

28040

Fundacion para Investigación Biomedica Hospital Clinico San Carlos, Madrid

All Listed Sponsors
lead

Hospital San Carlos, Madrid

OTHER

NCT03716934 - CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial | Biotech Hunter | Biotech Hunter